论文部分内容阅读
目的探讨前列腺特异性抗原(PSA)、高分子量细胞角蛋白(34βE12)、P63和α-甲基酰基辅酶A消旋酶(P504S)在前列腺癌中的表达及临床意义。方法运用免疫组化SP法检测92例前列腺癌(PA)、20例良性前列腺增生(BPH)和20例前列腺上皮内瘤(PIN)石蜡标本中PSA、34βE12、P63、P504S的表达。结果BPH、PIN和PA3组间34β%12、P63和P504S阳性表达率差异有统计学意义(P<0.01)。34β%12和P63阳性表达与前列腺癌的Gleason分级评分之间密切相关。膀胱尿路上皮癌PSA和34β%12呈阴性表达。结论PSA、P63、34β%12和P504S改良的免疫组化法和抗体联合染色应用可作为前列腺癌诊断和鉴别诊断的重要指标。
Objective To investigate the expression and clinical significance of prostate specific antigen (PSA), high molecular weight cytokeratin (34βE12), P63 and α-methylacyl-CoA gyrase (P504S) in prostate cancer. Methods The expressions of PSA, 34βE12, P63 and P504S in 92 cases of prostate cancer (PA), 20 cases of benign prostatic hyperplasia (BPH) and 20 cases of prostatic intraepithelial neoplasia (PIN) were detected by immunohistochemical SP method. Results The positive rates of 34β% 12, P63 and P504S in BPH, PIN and PA3 groups were significantly different (P <0.01). There was a close correlation between 34β% 12 and P63 positive expression and Gleason’s grading score of prostate cancer. Bladder urothelial carcinoma PSA and 34β% 12 were negative expression. Conclusion The improved immunohistochemistry and antibody combined staining of PSA, P63, 34β% 12 and P504S can be used as an important index in the diagnosis and differential diagnosis of prostate cancer.